Cadila Healthcare Ltd has received tentative approval from the United States Food and Drug Administration to market Pravastatin Sodium Tablets in the US market.
The tentative approval was given for strengths of 10 mg, 20 mg, 40 mg and 80 mg, the company informed the Bombay Stock Exchange.
The company would market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc, following patent expiry, it added.
The drug, which had branded sales of approximately $1.8 billion in the US market during 2005, is a lipid lowering agent.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group